Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Last Updated: 2026

Novocure

Rank#5110

Market Cap1.84B

CountryJersey

Summary

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

History

Novocure was founded on a big idea from Dr. Yoram Palti – professor of electrical engineering and a cancer survivor – to fight cancer with an innovative therapy called Tumor Treating Fields therapy. Novocure is dedicated to unlocking the potential of Tumor Treating Fields and improving the lives of cancer patients.

Mission

Our mission is to extend lives by developing, manufacturing and commercializing innovative cancer treatments that empower patients, their families and their physicians.

Vision

Our vision is to make Tumor Treating Fields therapy the standard of care for all solid tumor types.

References

https://in.investing.com/equities/novocure-ltd

https://finance.yahoo.com/quote/NVCR/profile?p=NVCR

https://www.crunchbase.com/organization/novocure

https://sec.report/CIK/0001645113

https://companiesmarketcap.com/

https://www.novocure.com

Leadership team

Mr. William F. Doyle (Exec. Chairman)

Mr. Asaf Danziger (Pres, CEO & Director)

Ms. Ashley Cordova (Chief Financial Officer)

Products / Services

Health Care, Medical Device

Number of Employees

1,000 - 20,000

Address

Jersey, Arkansas, United States

Established

2000-01-01

Company Registration

SEC CIK number: 0001645113

Revenue

500M - 1B

Traded as

NVCR

Website

https://www.novocure.com

Social Media

Last Updated: 2026

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More

Last Updated: 2026

Novocure

Rank#5110

Market Cap1.84B

CountryJersey

Summary

History

Mission

Our mission is to extend lives by developing, manufacturing and commercializing innovative cancer treatments that empower patients, their families and their physicians.

Vision

Our vision is to make Tumor Treating Fields therapy the standard of care for all solid tumor types.

References

https://in.investing.com/equities/novocure-ltd

https://finance.yahoo.com/quote/NVCR/profile?p=NVCR

https://www.crunchbase.com/organization/novocure

https://sec.report/CIK/0001645113

https://companiesmarketcap.com/

https://www.novocure.com

Leadership team

Mr. William F. Doyle (Exec. Chairman)

Mr. Asaf Danziger (Pres, CEO & Director)